IMRN חוב כולל להון Immuron

This chart of current Immuron Limited (IMRN) quotes shows a debt-to-equity ratio of 0.00, driven by Travelan sales in the US. Immuron Limited (IMRN) relies on the defensive qualities of gastrointestinal immunotherapy, maintaining revenue regardless of economic conditions. Business growth is based on the global expansion of pharmacy chains and the automation of colostrum capsule production.

This indicator measures financial leverage by comparing total liabilities to equity to assess the business's reliance on external financing. An analysis of the debt-to-equity ratio confirms the stability of Immuron Limited (IMRN), whose over-the-counter drug expansion strategy and sales growth in the gastrointestinal segment are supported by stable management without a critical debt load.